Alvotech’s Simponi Biosimilar Steps Into Phase III RA Study

‘ALVOFLEX’ Trial Follows Recent Phase I PK Study For AVT05 Candidate

 
• By Dean Rudge

Alvotech has marked another milestone by moving its proposed biosimilar to Simponi (golimumab) into Phase III comparison studies.

Robert Wessman Alvogen Alvotech
Robert Wessman became Alvotech CEO in January • Source: Alvotech

More from Biosimilars

More from Products